Related Experiment Video
Updated: May 7, 2026

Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations
Published on: October 20, 2017
Endovascular Embolization for Chronic Subdural Hematomas: A Literature Review of the Current Evidence
Andrés Sebastián Estrella López1, Naomi Pauleth Espin Jiménez2, Patricio Alejandro Montalvo Ramos3
1Public Health, NeoScientia Consulting Group, Quito, ECU.
Insights
Middle meningeal artery (MMA) embolization shows promise for treating chronic subdural hematoma (cSDH), potentially reducing recurrence compared to surgery, especially in high-risk patients. Further research is needed to clarify optimal use and effectiveness.
Area of Science:
- Neurosurgery
- Interventional Radiology
- Vascular Surgery
Background:
- Chronic subdural hematoma (cSDH) is a significant cause of disability, particularly in elderly patients.
- Standard surgical treatments for cSDH have limited success rates and frequent recurrences.
- Middle meningeal artery (MMA) embolization is emerging as an alternative treatment strategy.
Purpose of the Study:
- To review the current evidence on the safety and effectiveness of MMA embolization for cSDH treatment.
- To evaluate MMA embolization as an alternative or adjunctive therapy to conventional surgical procedures.
- To identify gaps in current research regarding MMA embolization for cSDH.
Main Methods:
- Systematic review of existing literature on MMA embolization for cSDH.
- Analysis of studies comparing MMA embolization with standard surgical evacuation (burr hole drainage, craniotomy).
- Evaluation of MMA embolization as standalone therapy versus adjunctive therapy.
Main Results:
- MMA embolization demonstrates potential for better recurrence prevention than surgery in patients with comorbidities.
- As adjunctive therapy, MMA embolization significantly reduces recurrence, rescue rates, and complications in complex/recurrent cSDH.
- Evidence for MMA embolization in less complex cSDH cases suggests better clinical outcomes.
- Overall effectiveness for all cSDH patients remains inconclusive due to limitations in current research.
Conclusions:
- MMA embolization is a promising treatment for cSDH, particularly in high-risk surgical patients.
- Further high-quality, large-scale randomized controlled trials are necessary to establish definitive guidelines.
- Optimal patient selection, embolic agent, and cost-effectiveness require further investigation.
Abstract:
Chronic subdural hematoma (cSDH) primarily affects elderly patients along with those who have multiple health problems, while it develops when blood collects between the dura mater and the brain. The condition results in substantial disability while also causing surgical treatment failures in certain cases. The occurrence of cSDH becomes more frequent as people age beyond 65 years old, which establishes this condition as a major health issue. The standard surgical evacuation method for treating this condition shows limited success because patients experience frequent recurrences, which motivates researchers to study endovascular embolization as an alternative treatment option. The promising endovascular embolization technique uses middle meningeal artery (MMA) embolization to target the blood supply of the neo-membrane surrounding the hematoma, thus preventing rebleeding and reducing recurrence. The available data shows that embolization of the MMA leads to better recurrence prevention than conventional surgical procedures among patients who face restrictions for surgery because of multiple health issues. The review analyzes current research about MMA embolization safety together with its effectiveness and appropriate applications for cSDH treatment. The existing evidence about endovascular embolization as adjunctive therapy to surgical procedures such as burr hole drainage or craniotomy provides a significant impact over standalone treatment for complex and recurrent cSDH cases, reducing recurrence, rescue rates, and complications. However, endovascular embolization also shows better clinical outcomes in reducing these outcomes, but for less complex cSDH cases. There is unclear or inconclusive evidence for overall cSDH patients because current research lacks large multicenter randomized controlled studies together with stringent quality standards and contains various patient groups and minimal study durations. The procedure's effectiveness remains unclear because researchers have not determined the best patient selection criteria, the most suitable embolic agent, or the most economical approach.
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology

